Undermining Value-Based Purchasing — Lessons from the Pharmaceutical Industry
Although it's not yet clear how health care providers will respond to value-based payment models, an examination of pharmaceutical industry practices can provide insights into problems that may arise — and practices to avoid. In 2015, the U.S. Department of Health and Human Services announced a...
Saved in:
| Published in: | The New England journal of medicine Vol. 375; no. 21; pp. 2013 - 2015 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Massachusetts Medical Society
24.11.2016
|
| Subjects: | |
| ISSN: | 0028-4793, 1533-4406 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Although it's not yet clear how health care providers will respond to value-based payment models, an examination of pharmaceutical industry practices can provide insights into problems that may arise — and practices to avoid.
In 2015, the U.S. Department of Health and Human Services announced a goal of linking at least 50% of Medicare spending to value-based payment models such as accountable care organizations.
1
Health care providers are now scrambling to reorganize in a way that delivers value while preserving or enhancing commercial success. Although it’s not yet clear how providers will respond to value-based payment models, an examination of pharmaceutical industry practices can provide insights into problems that may arise — and practices to avoid.
Value-based plan design — a term that describes payers’ efforts to align consumer cost sharing with the value . . . |
|---|---|
| Bibliography: | SourceType-Scholarly Journals-1 ObjectType-Commentary-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
| ISSN: | 0028-4793 1533-4406 |
| DOI: | 10.1056/NEJMp1607378 |